Copyright
©2012 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Jan 7, 2012; 18(1): 44-48
Published online Jan 7, 2012. doi: 10.3748/wjg.v18.i1.44
Influence of proton pump inhibitor treatment on Helicobacter pylori stool antigen test
Masaaki Kodama, Kazunari Murakami, Tadayoshi Okimoto, Yoshihiro Fukuda, Tadashi Shimoyama, Masumi Okuda, Chieko Kato, Intetsu Kobayashi, Toshio Fujioka
Masaaki Kodama, Kazunari Murakami, Tadayoshi Okimoto, Toshio Fujioka, Department of Gastroenterology, Faculty of Medicine, Oita University, Yufu city, Oita 879-5593, Japan
Masaaki Kodama, Faculty of Medicine, Hasama Division, Health Science Center, Oita University, Yufu city, Oita 879-5593, Japan
Yoshihiro Fukuda, Masumi Okuda, General Medicine and Community Health Science, Hyogo College of Medicine, Hyogo 663-8501, Japan
Tadashi Shimoyama, Department of Gastroenterology, Hirosaki University, Graduate School of Medicine, 5zaifu-cho, Hirosaki 036-8562, Japan
Chieko Kato, Toyama City Medical Association Health Management Center, Kyodo, Toyama 930-0951, Japan
Intetsu Kobayashi, Department of Microbiology, Toho University, Ota-ku, Tokyo 143-8540, Japan
Author contributions: Kodama M, Fukuda Y, Shimoyama T, Fujioka T made this study plan; Kodama M, Okimoto T, Murakami K collecting samples for using UBT and Stool antigen test; Shimoyama T, Okuda M, Kato C, and Kobayashi I measured and analyzed UBT and stool antigen test.
Correspondence to: Masaaki Kodama, MD, PhD, Department of Gastroenterology, Faculty of Medicine, Oita University, Yufu city, Oita 879-5593, Japan. kodm@oita-u.ac.jp
Telephone: +81-975-866193 Fax: +81-975-866194
Received: February 25, 2011
Revised: July 6, 2011
Accepted: July 11, 2011
Published online: January 7, 2012
AIM: To investigate the effects of proton pump inhibitor (PPI) treatment on stool antigen test using the TestMate pylori enzyme immunoassay.
METHODS: This study assessed 28 patients [16 men and 12 women; mean age (63.1 ± 5.9) years; range, 25-84 years] who underwent stool antigen test and urea breath test (UBT) before and after PPI administration.
RESULTS: Using the UBT as the standard, the sensitivity, specificity and agreement of the stool antigen test in all 28 patients were 95.2%, 71.4%, and 89.3%, respectively, before PPI administration, and 88.9%, 90.9%, and 89.3%, respectively, after PPI treatment. Mean UBT values were 23.98% ± 5.33% before and 16.19% ± 4.75% after PPI treatment and, in 15 patients treated for ≥ 4 wk, were significantly lower after than before 4 wk of PPI treatment (12.58% ± 4.49% vs 24.53% ± 8.53%, P = 0.048). The mean optical density (A450/630) ratios on the stool antigen test were 1.16 ± 0.20 before and 1.17 ± 0.24 after PPI treatment (P = 0.989), and were 1.02 ± 0.26 and 0.69 ± 0.28, respectively, in the group treated for > 4 wk (P = 0.099).
CONCLUSION: The stool antigen test was equally sensitive to the UBT, making it a useful and reliable diagnostic method, even during PPI administration.
